Abstract
The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Current Bioactive Compounds
Title: Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Volume: 4 Issue: 2
Author(s): Vijaya L. Korlipara
Affiliation:
Keywords: TRPV1 receptor antagonists, vanilloids, structure activity relationships, agonist binding site, pain modulation
Abstract: The TRPV1 vanilloid receptor, first cloned and characterized in 1997, is a non selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. Activators of this receptor are varied and include capsaicin, the pungent phenolic principle from hot chilli peppers, endogenous lipid anandamide, noxious heat, and low extracellular pH. Agonists of the TRPV1 receptor have been investigated for development due to their analgesic effect that results from the receptor desensitization. However, all agonists including capsaicin cause initial burning effect, and have the potential for other undesirable effects, which complicates effective therapy. The development of animal pain models involving TRPV1 receptor blockade through small molecules and characterization of TRPV1 knockout mice models in recent years has provided a compelling argument in favor of pursuing the development of selective TRPV1 antagonists as novel analgesic agents. This article will provide an overview of the various chemical classes of agonists and antagonists of TRPV1 receptor along with their therapeutic potential and possible side effects.
Export Options
About this article
Cite this article as:
Korlipara L. Vijaya, Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294235
DOI https://dx.doi.org/10.2174/157340708785294235 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of Endothelin and Insulin: Expanding Parameters of Insulin Resistance
Current Diabetes Reviews Identification of GCP II Inhibitors Based on 4-Arylmethyl-3-(4- carboxyphenyl)-5-hydroxyisoxazole Scaffold
Letters in Drug Design & Discovery Clinical Implication of Meissner’s Corpuscles
CNS & Neurological Disorders - Drug Targets Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Editorial (Thematic Issue: “An Overview on Proteins of Biomedical Importance in Targeted Therapy of Cancer, Duchenne Muscular Dystrophy and Protein Misfolding Associated Neuropathy: Structure Function Relationship, Mechanism of Action, Role of Small Molecule Antagonist and Future Perspective”)
Current Chemical Biology Genes Involved in Hereditary Hearing Impairment
Current Genomics Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design An Overview on Inventions Related to Ginger Processing and Products for food and Pharmaceutical Applications
Recent Patents on Food, Nutrition & Agriculture Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design A Hybrid PSO-DEFS Based Feature Selection for the Identification of Diabetic Retinopathy
Current Diabetes Reviews Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Gabapentin for the Treatment of Cancer-Related Pain Syndromes
Reviews on Recent Clinical Trials Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued)